mendeley

    Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**

    DOI Logo 10.17352/ahr.000003

    Published On: December 30, 2015 | Pages: 009 - 017

    Author(s): Roberto Focaccia*, Rodolfo Ferreira de Mello, Patrícia Silva Montes and Flávio Martin Conti
    Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to interferon (IFN). IFN-free treatments are now considered elective drugs for patients with chronic HCV. More than 90% of patients infected with HCV ge ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos
    Abstract View Full Article View
    mendeley

    Association of the Treatment Induced Clearance of Hepatitis C Virus Infection with the IL28B Gene Polymorphisms

    DOI Logo 10.17352/ahr.000002

    Published On: December 28, 2015 | Pages: 005 - 008

    Author(s): Pavlina Dzekova Vidimliski, Igor G Nikolov, Nadica Matevska Geshkovska, Yana Boyanova, Nina Nikolova, Grigore Romanciuc, Dan Dumitrascu, Viktorija Caloska- Ivanova, Nenad Joksimovic, Krasimir Antonov, Lyudmila Mateva, Lionel Rostaing, Aleksandar Dimovski, Aleksandar Sikole*
    Background: It has been shown that single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) gene were associated with sustained viral response following standard treatment of hepatitis C virus infection. Aim: The aim of the study was to evaluate the association between the SNPs near the IL28B gene and the response to the treatment of chronic hepatitis ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos
    Abstract View Full Article View
    mendeley

    Current Trends of Combination Therapy in Chronic Hepatitis B Management in China

    DOI Logo 10.17352/ahr.000001

    Published On: August 28, 2015 | Pages: 001 - 004

    Author(s): En-Qiang Chen*
    In the past decade, five oral nucleos(t)ide analogs and two formulations of pegylated interferon alpha have been approved for the treatment of chronic hepatitis B (CHB). Due to low personal income and inadequate health care system, low-to-moderate genetic barrier antiviral drugs are still widely used in China, which brings increased suboptimal response, viral relapse ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos
    Abstract View Full Article View

     

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on AHR